False positives and false negatives can both do harm to patients

**False positives**
- Unnecessary treatment impacts patients’ lives
- Needless emotional burden of patient
- Unneeded procedures can cause pain and harm to the patient
- Time lost by clinician and patient
- Undue financial costs to patient

**False negatives**
- False sense of security for patient
- Patient may go up to 5 years before being screened again

The cobas® HPV Test increases patient safety by striving to eliminate false negative and false positive results.

**Why wait to get all the answers she needs?**

The cobas® HPV Test allows you to manage your patients with greater precision and efficiency by individually identifying the highest-risk genotypes, HPV16 and HPV18, while simultaneously providing pooled results for the twelve other hrHPV genotypes.

**For additional information, please visit www.hpv16and18.com or call 1-877-906-8983.**

**References**

COBAS and LIFE NEEDS ANSWERS are trademarks of Roche.
©2013 Roche Diagnostics. All rights reserved. 472-52491-0513
What determines cervical cancer risk?

When determining the risk of cervical cancer, you must have confidence in your HPV test to deliver the most accurate and reliable results.

Clinicians expect results that are accurate and reliable, and patients deserve them.

The cobas® HPV Test gives you the confidence to deliver reliable results for all your HPV testing needs.

**Reflex testing**
- For women with ASC-US cytology

**Co-testing**
- ACOG prefers over reflex testing for women 30 to 65 years old

**Genotyping**
- Identifying HPV16 and HPV18 for best risk assessment

---

**cobas® HPV Test**

**Detects HPV DNA**
Organizations such as ACOG, ACS, ASCCP, and NCCN base their screening guidelines on results obtained from HPV tests that detect DNA.

**Internal cellular control**
A true negative result using the cobas HPV Test will show a negative result for HPV, but will always show the presence of human β-globin from the patient's cells. The internal control monitors the presence of human cells and the completion of the entire test process.

**No cross-reactivity**
The design of the cobas HPV Test drives hrHPV genotype specificity to help eliminate cross-reactivity with low-risk HPV genotypes. The cobas HPV Test is the only IVD test without an FDA-required disclosure of low-risk cross-reactivity.

**Small 1 mL sample size**
The cobas HPV Test uses a small sample size to help eliminate the inconvenience of patient call-backs, due to Quantity Not Sufficient (QNS) results.

**Identifies all 14 hrHPV genotypes**
The cobas HPV Test uses a small sample size to help eliminate the inconvenience of patient call-backs, due to Quantity Not Sufficient (QNS) results.

**Identifies all 14 hrHPV genotypes**
The cobas HPV Test detects all fourteen hrHPV genotypes – 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The oldest HPV test on the market, HC2 (Qiagen) only detects thirteen.

**3 results in 1 test**
The cobas HPV Test is the only clinically validated, FDA-approved assay that simultaneously provides individual results on the highest-risk genotypes – HPV16 and HPV18 – and a pooled result on the twelve other hrHPV genotypes. This allows genotyping to take place during co-testing. No other HPV test does this!

**FDA approved**
The ATHENA Study is the largest US-based cervical cancer clinical trial. Using a test that is clinically-validated through the landmark ATHENA Study provides confidence in the clinical reliability, relevance, and accuracy of its performance.